Davion Healthcare Plc (DAVI) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, DAVI scores 47 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The score is built from five pillars. The fundamental cash engine scores 12 of 20, with ROIC at 0% and FCF yield at 0%, meaning the rating reports no measurable return on invested capital and no free cash flow yield. Whale/13F flow scores 3 of 20, the weakest pillar, reflecting institutional accumulation and options positioning signals that the rating treats as unsupportive. Insider conviction scores 9 of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 10 of 20, with beta at 1.0 and sector sensitivity as the stated basis. Forensic balance sheet scores 13 of 20, citing Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5.

For a prospective investor, the pillar profile points to weak cash generation and weak institutional support, partly offset by a balance sheet the rating considers moderately sound. Upside drivers would need to come from improvements in cash returns and ownership flow, which the rating does not currently show. The 0% ROIC and 0% FCF yield mean the valuation case rests on factors outside the cash engine, and the source data does not supply valuation multiples to test that. The rating's "distribution warning" label signals the rating's view that current conditions favor caution over accumulation.

Davion Healthcare Plc (DAVI) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the profile. The profile does not describe its products, customers, or revenue model. Not available in source data for the specifics of what the company sells, to whom, or how it earns revenue.

Per the recent news feed, the most recent headline (published 1h ago, rated RED, impact label RISK WATCH) states that the company confirmed an expected NASDAQ trading date and announced new executive leadership and an operating structure. The headline's summary is generic and does not describe the substance of the leadership or structure changes. Other items, all rated YELLOW with impact label MARKET WIRE, include a Barron's stock overview, a Yahoo Finance UK quote page, a Stock Titan profile, a Simply Wall St company information page, and a Timothy Sykes item headlined that DAVI stock slid as volatility gripped the company, published 2d ago. Per the market data, the stock is down -18.24% on the day and trades near the bottom of its 52-week range. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. The source data therefore identifies no upstream suppliers, downstream customers, or sector correlation pathways. Not available in source data for dependency mapping or 2nd-order bottleneck analysis. The sector and industry classification (Health Care; Medical/Dental Instruments) is the only available context.

• What products or services does Davion Healthcare generate revenue from, and who are its customers?
• What are the reported revenue, operating income, net income, free cash flow, cash, and debt figures across recent periods?
• What do the new executive leadership and operating structure announcements change about the company's strategy or cost base?
• Why does the rating show 0% ROIC and 0% FCF yield, and are these zero values or missing data?
• Who holds the shares and what insider, 13F, or Congressional trades have occurred?